Catalent has announced plans to acquire Cook Pharmica for $950m.
The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.
Both the acquirer and target entities are pharmaceutical companies based in the US.
Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m.
The acquisition will strengthen the company’s business and help in accelerating the development of its therapeutics.
See Also:
Both companies involved in the acquisition are based in the US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData